Cargando…

Current and novel drug therapies for idiopathic pulmonary fibrosis

Over the past decade, there has been a cohesive effort from patients, physicians, clinical and basic scientists, and the pharmaceutical industry to find definitive treatments for idiopathic pulmonary fibrosis (IPF). As understanding of disease behavior and pathogenesis has improved, the aims of thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adamali, Huzaifa I, Maher, Toby M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463380/ https://www.ncbi.nlm.nih.gov/pubmed/23055696 http://dx.doi.org/10.2147/DDDT.S29928

Ejemplares similares

A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis
por: Sharp, Charles, et al.
Publicado: (2017)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services
por: Barratt, Shaney L, et al.
Publicado: (2021)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

Ganciclovir Antiviral Therapy in Advanced Idiopathic Pulmonary Fibrosis: An Open Pilot Study
por: Egan, J. J., et al.
Publicado: (2011)

South–West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
por: Barratt, Shaney L., et al.
Publicado: (2018)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives
por: Zulfikar, Sabrina, et al.
Publicado: (2020)

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

The Role of the Lung’s Microbiome in the Pathogenesis and Progression of Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2019)

The topical study of inhaled drug (salbutamol) delivery in idiopathic pulmonary fibrosis
por: Usmani, Omar S., et al.
Publicado: (2018)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Global incidence and prevalence of idiopathic pulmonary fibrosis
por: Maher, Toby M., et al.
Publicado: (2021)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Idiopathic pulmonary fibrosis: Current and future treatment
por: Glass, Daniel S., et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: current diagnosis and treatment
por: Amaral, Alexandre Franco, et al.
Publicado: (2023)

Cell Therapy in Idiopathic Pulmonary Fibrosis†
por: Serrano-Mollar, Anna
Publicado: (2018)

Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis
por: Kolb, Martin, et al.
Publicado: (2023)

Pulmonary fibrosis associated with psychotropic drug therapy: a case report
por: Thornton, Clare, et al.
Publicado: (2009)

Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives
por: Collum, Scott D., et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

The therapy of idiopathic pulmonary fibrosis: what is next?
por: Somogyi, Vivien, et al.
Publicado: (2019)

Current therapies for patients with acute exacerbation of idiopathic pulmonary fibrosis
por: Zhu, Li-Li, et al.
Publicado: (2020)

Pulmonary (18)F-FDG uptake helps refine current risk stratification in idiopathic pulmonary fibrosis (IPF)
por: Win, Thida, et al.
Publicado: (2018)

Regenerative medicine in the treatment of idiopathic pulmonary fibrosis: current position
por: Álvarez, Diana, et al.
Publicado: (2015)

Candidate genes of idiopathic pulmonary fibrosis: current evidence and research
por: Zhou, Wei, et al.
Publicado: (2016)

Obstacles to early treatment of idiopathic pulmonary fibrosis: current perspectives
por: Moua, Teng, et al.
Publicado: (2019)

Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential
por: Raghu, Ganesh
Publicado: (2017)

Idiopathic pulmonary fibrosis
por: Meltzer, Eric B, et al.
Publicado: (2008)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Gene therapy strategies for idiopathic pulmonary fibrosis: recent advances, current challenges, and future directions
por: Ruigrok, Mitchel J.R., et al.
Publicado: (2021)

Circulating fibrocytes are not disease-specific prognosticators in idiopathic pulmonary fibrosis
por: Stewart, Iain D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ogtnt4ljpqavtl3372m8ji66hq